Aimmune Therapeutics Reports License Of Exclusive Global Rights To Xencor's XmAb 7195 For Development Of Next-Gen Food Allergy Treatments; Aimmune to Make Upfront Payment To Xencor Of $5M In Cash, $5M In Equity
Benzinga Newsdesk